HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor 2 negative) breast cancer accounts for ~70% of the total diagnosed BC cases worldwide, in which biological characteristics and prognosis are distinctly different from other subtypes (HER2 positive subtype/triple-negative subtype) (9). This evidence concerns the gene NR4A1 and breast cancer.